Figure 1:
Figure 1A: PET/CT scan at initial diagnosis showed multiple fluorodeoxyglucose (FDG)-avid lymph nodes above and below diaphragm, including cervical, mediastinal, axillary, abdominal, and inguinal nodal stations.
Figure 1B: PET/CT scan after 2 cycles of therapy showed resolution of previous FDG-avid lymph nodes seen in Fig. 1A.
Figure 1C: PET/CT scan after 5 cycles of chemotherapy (completion of therapy) showed new anterior mediastinal mass, new intraabdominal FDG-avid lesion and increased activities of bilateral axillary lymph nodes. This scan was concerning for progression of disease.
Figure 1D: PET/CT scan after 2 cycles of rituximab and bendamustine showed new and worsening lymphadenopathy above and below the diaphragm, concerning for interval progression of PTLD.